Trade Alert: AI Optics, Neurotech, And Infrastructure
Bullish options bets on our system's #1 name (a 2x previous winner for us this year), and on one of our Multibaggers names and on two of our Market Watchers names.
Taking Multiple Swings Again
One reason we’ve been using several trades in some alerts lately is that the market has been rewarding the right themes quickly.
That means that when a stock sits in a live theme, passes our screens, and gives us attractive options pricing, we want exposure to it ASAP.
When that name is a previous winner for us, we want that even more.
One of today’s trades is in a name that has already been a 2x winner for us this year. We also entered another trade on it last month. But it was Portfolio Armor’s #1 name last night, it remains tied to a strong theme, and it passed our technical screens again. So we’re adding another trade, going further out than our last one to give us additional exposure with some temporal diversity.
A Biotech Catalyst Worth Watching
We’re also adding a biotech special-situation trade today.
The stock is ClearPoint Neuro (CLPT 0.00%↑), and the related catalyst is uniQure (QURE 0.00%↑). One of the biotech specialists on our Multibaggers X list has been pounding the table on both this week because he thinks the FDA may be moving back toward a more flexible posture on rare-disease and gene-therapy approvals, including the use of real-world evidence and existing scientific knowledge.
That matters because QURE’s AMT-130, a Huntington’s disease gene therapy, previously produced strong clinical data, but later ran into FDA pushback over whether its Phase I/II data and external-control comparison were enough to support approval without a new prospective sham-surgery-controlled study. uniQure said the FDA strongly recommended that kind of study in a March regulatory update. (uniqure BV)
That raises obvious ethical concerns. Huntington’s is a devastating, fatal disease, and a sham-surgery-controlled trial would mean some patients literally get holes drilled in their heads without receiving the actual gene therapy. That’s a much higher bar than asking patients to take a placebo pill.
CLPT matters here because its neurosurgical navigation and delivery platform has been involved in AMT-130 administration. ClearPoint previously described the U.S. AMT-130 Phase I/II study as using its ClearPoint Neuro Navigation System and SmartFlow MRI-safe cannulae under MRI guidance. (ClearPoint Neuro, Inc.)
So why are we adding a trade on CLPT today rather than QURE?
Because CLPT is the one that passes our technical screens now. We recently added a new QURE trade too, so we already have extra exposure there. Today’s CLPT trade gives us extra exposure to the delivery side of the same potential regulatory rerating while sticking with our process: live catalyst, strong theme, defined risk, and a stock that passes our screens.
Today’s Other Themes
The rest of today’s alert stays in the same broader lane we’ve been working: AI optical testing, positioning/navigation infrastructure, and AI data-center infrastructure.
As usual, we’re using options structures designed to use high implied volatility to our advantage, and we priced these structures using Black-Scholes as a baseline, Bjerksund-Stensland as an American-style option check, and Cox-Ross-Rubinstein binomial tree modeling where path-sensitive issues could matter. We’re aiming to enter at prices that are attractive relative to modeled fair value, and rather than chase these trades, we’re letting the market come to us.
Full details, including our pre-set exit orders, so we don’t have to babysit these trades, are below.
Today’s Top Names Trade
AI optical testing / network-validation theme
